Lutikizumab + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Jun 27, 2024 → Dec 1, 2026

NCT ID

NCT06468228

About Lutikizumab + Placebo

Lutikizumab + Placebo is a phase 3 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06468228. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

🔄adalimumab + placeboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06718101	Phase 2	Active	Dec 19, 2024	May 1, 2027	Atopic Dermatitis
NCT06468228	Phase 3	Recruiting	Jun 27, 2024	Dec 1, 2026	Hidradenitis Suppurativa
NCT05139602	Phase 2	Active	Dec 28, 2021	Dec 1, 2027	Hidradenitis Suppurativa

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39